Mutations in the mitochondrially located protein CHCHD10 cause motoneuron disease by an unknown mechanism. In this study, we investigate the mutations p.R15L and p.G66V in comparison to wild-type CHCHD10 and the non-pathogenic variant p.P34S in vitro, in patient cells as well as in the vertebrate in vivo model zebrafish. We demonstrate a reduction of CHCHD10 protein levels in p.R15L and p.G66V mutant patient cells to approximately 50%. Quantitative real-time PCR revealed that expression of CHCHD10 p.R15L, but not of CHCHD10 p.G66V, is already abrogated at the mRNA level. Altered secondary structure and rapid protein degradation are observed with regard to the CHCHD10 p.G66V mutant. In contrast, no significant differences in expression, degradation rate or secondary structure of non-pathogenic CHCHD10 p.P34S are detected when compared with wild-type protein. Knockdown of CHCHD10 expression in zebrafish to about 50% causes motoneuron pathology, abnormal myofibrillar structure and motility deficits in vivo. Thus, our data show that the CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease primarily based on haploinsufficiency of CHCHD10.
Introduction
Impairment of mitochondria has repeatedly been suggested to contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS) (1, 2) . However, the observed mitochondrial alterations may be secondary events, and genetic support for mitochondrial dysfunction as a primary cause of motoneuron degeneration was still lacking. However, recently, rare missense mutations in the coiled-coil-helix-coiled-coil-helix domain containing protein 10 (CHCHD10) were linked to a diverse disease spectrum including myopathy, cerebellar ataxia, frontotemporal dementia (FTD) (3) as well as motoneuron diseases (MND), specifically ALS (3, 4) and spinal muscular atrophy Jokela type (SMAJ) (5, 6) .
CHCHD10 is a nuclear gene, but expression of its protein product is mainly limited to mitochondria (3) . CHCHD10 is part of the mitochondrial contact site and cristae organizing system (MICOS) complex at the inner mitochondrial membrane (7) . No major mitochondrial structural changes were observed in SMAJ muscle tissue (8) while it has been shown that ALS-and FTDcausing CHCHD10 mutations lead to structural and functional impairments of mitochondria (3, 7) . Therefore, CHCHD10 mutations could provide the first human genetic evidence that primary mitochondrial damage can cause MND. However, it remained largely unclear whether motoneuron disease-causing mutations in CHCHD10 lead to a loss of physiological function, a dominant-negative effect as suggested by very recent work (9) or novel toxic properties completely unrelated to its physiological role. Distinguishing between these possibilities is central to the understanding of CHCHD10-related neurodegeneration and the role of mitochondrial damage in motoneuron diseases. Respective insights have also been hampered by the lack of biomaterial from a sufficient number of rare CHCHD10 mutation carriers and the predominant use of overexpression models (3, 7, 9) .
In this study, we use cell lines of a total of 13 patients to show that the CHCHD10 mutations p.R15L and p.G66V cause MND by reduced expression of the mutant protein and haploinsufficiency of CHCHD10. We furthermore corroborate our findings by biochemical assays and an in vivo zebrafish model.
Results
The subsequent studies are based on the two motoneuron disease-associated CHCHD10 mutations with the strongest evidence for causality: CHCHD10 G66V is a rare variant which has been shown to co-segregate with a lower motoneuron syndrome in 17 Finnish families (5) and was found in one familial index patient (4) . CHCHD10 R15L is another rare variant that has been detected in three German families (4, 10) as well as three ALS families in the United States (11) . As a control condition in addition to wild-type (WT) CHCHD10 we used CHCHD10
P34S
. The p.P34S variant of CHCHD10 represents a polymorphism with a frequency of overall 0.6% in control populations and has been shown not to be associated with ALS in multiple studies (12, 13) .
p.R15L and p.G66V mutations lead to reduced CHCHD10 protein levels in patient-derived cells Western blot analysis of ALS patient-derived lymphoblastoid cell lines (LCLs) and primary fibroblasts carrying the CHCHD10 p.R15L and p.G66V mutation, respectively, revealed an approximately 50% reduction in protein levels compared with healthy controls (Fig. 1A, Supplementary Material, Fig. S1 ). The total amount of mitochondria was not affected in patient cells as suggested by Western blotting of the mitochondrial marker HSP60 (Fig. 1B,  Supplementary Material, Fig. S1 ) and quantitative real-time PCR (qRT-PCR) of four mitochondrially encoded genes (Fig. 1C) . Additionally, transmission electron microscopy (TEM) did not reveal altered mitochondrial ultrastructure in patient-derived cells (Fig. 1D) . qRT-PCR demonstrated a reduction of CHCHD10 mRNA to approximately 50% in the heterozygous CHCHD10 R15L mutant patient cells (Fig. 1E ). Subsequent sequencing of the respective cDNA revealed a complete loss of CHCHD10 R15L mutated mRNA, while expression of the WT allele was confirmed (Fig. 1F) . LCLs carrying the p.P34S variant, which is not associated with ALS, did not reveal any changes of CHCHD10 mRNA or protein expression, and sequencing of the CHCHD10 cDNA indicated similar expression of both alleles. In fibroblasts of CHCHD10 G66V mutation carriers, TDP-43 staining did not reveal a nucleocytoplasmic translocation of TDP-43 (at least 100 cells analysed per condition), which contrasts with results from a previous report based on CHCHD10 knockdown in primary mouse neurons and murine neuronal NIH3T3 cells (9) . Additionally, we could not detect any accumulation of cytoplasmic stress granules, as judged by staining of TIAR (Fig. 1G) .
CHCHD10 p.G66V shows an increased degradation rate
We found that both mutations, CHCHD10 R15L and CHCHD10
G66V
, lead to an approximately 50% decrease in CHCHD10 protein level. In contrast to CHCHD10 R15L , CHCHD10
G66V mRNA was normally expressed. Therefore, we hypothesized that the reduction in CHCHD10 G66V protein was the result of instability and increased degradation on the protein level. Consequently, we performed a pulse-chase experiment in HEK293 cells overexpressing CHCHD10 for 24 h, followed by cycloheximide (CHX, 30 mg/ml) treatment to inhibit protein translation for up to 6 h ( Fig. 2A) . Subsequent quantitative analysis of the CHCHD10 protein level by Western blotting showed substantially increased degradation rates of CHCHD10 G66V compared with CHCHD10 WT and CHCHD10 P34S after 6 h of CHX treatment (Fig. 2B ). In addition, CHCHD10 R15L protein displayed a trend towards faster degradation. Next, we employed circular dichroism spectroscopy to study recombinant CHCHD10 protein (Fig. 2C) . Overall, the spectra had expected shapes, considering that the predicted structure of CHCHD10 consists of long disordered regions and three a-helices. After addition of 0.1% DPC, mimicking membrane conditions, both CHCHD10 R15L and CHCHD10 G66V showed distinct structural differences with an increased a-helical content when compared with CHCHD10 WT and the non-pathogenic CHCHD10 P34S variant (Fig. 2D ). This suggests that improper protein folding may induce an increased degradation rate of CHCHD10 pathogenic variants. The fact that these differences are pronounced under membrane-mimicking conditions can be explained by the fact that CHCHD10 R15L and CHCHD10
are both more hydrophobic than CHCHD10
WT .
In vivo knockdown of CHCHD10 in zebrafish leads to neuronal and muscular pathology as well as impaired locomotion
As our data obtained from patient-derived cells and biochemical experiments suggested haploinsufficiency of CHCHD10 protein as the predominant pathogenic consequence of CHCHD10 G66V and CHCHD10 R15L mutations, we next aimed to validate this molecular genetic mechanism in vivo. Accordingly, we induced a transient knockdown in zebrafish embryos using two different morpholinos directed against the translation initiation site (MO1) or a splice site (MO2, exon1-intron1) of CHCHD10 pre-mRNA. A standard control morpholino (CoMO) served as injection control. Human and zebrafish CHCHD10 share about 66% sequence identity at the protein level with a high conservation of the characteristic hydrophobic helix and the C-terminal CHCH-domain (Fig. 3A) . Confirmation of CHCHD10 knockdown to approximately 50% by both morpholinos at 48 hours post fertilization (hpf) was based on mass spectrometric analysis ( Fig. 3B ), as no antibody directed against Danio rerio CHCHD10 orthologue was available. We thus achieved a degree of CHCHD10 protein knockdown that resembles the situation in human CHCHD10 mutant cells. The CHCHD10 knockdown did not alter gross morphology of the fish except for an unspecific heart edema that is most likely caused by the injection procedure since it is also observed in control morpholino-injected embryos (Fig. 3C ). However, in an unbiased hierarchical cluster analysis of the proteomic profiles obtained from zebrafish embryos that were injected with MO1, MO2, CoMO or remained uninjected, biological replicates from each condition clustered together, suggesting that the different treatments resulted in distinct but consistent alterations of the proteome (Fig. 3D ).
Non-injected and CoMO-injected controls, as well as MO1-and MO2-injected embryos clustered together, respectively, indicating similar alterations of the proteome by CHCHD10 knockdown irrespective of the morpholino used, and little changes caused by the control morpholino. Furthermore, both MO1-and MO2-mediated knockdown of CHCHD10 led to a similar pathology: Both morphants showed motoneuron pathology with significantly reduced axon lengths (Fig. 3E) . Moreover, MO1-as well as MO2-injection led to a significant reduction of light polarization by myofibrils, indicating a disturbance of the normally highly ordered structure of the zebrafish skeletal muscle Table S2 ). Mitochondrial ultrastructure in muscle tissue appeared normal as shown in TEM images in Figure 4A (lower panel). Thus, our zebrafish CHCHD10 knockdown model is reminiscent of both the neuronal and myopathic phenotypes observed in MND patients carrying a CHCHD10 mutation.
The observed cellular abnormalities resulted in functional deficits. CHCHD10 knockdown embryos showed a decrease in the touch-induced flight response (Fig. 4C , Supplementary Materials, Videos). Both, the functional and the above described neuromuscular phenotype, could be rescued by coinjection of morpholino with CHCHD10 mRNA (Supplementary (Bars represent mean 6 s.e.m; ***P 0.001 in a two-tailed student's t-test) (C) Coomassie-stained SDS-gel of recombinant CHCHD10 variants purified from E. coli and used for CD spectroscopy. (D) CD spectra of purified CHCHD10 proteins. Spectra were acquired in PBS with 0.02% (thin lines) and 0.1% (thick lines) dodecylphosphocholine (DPC). The higher concentration, being above the critical micellar concentration, mimics membrane conditions. The spectra of CHCHD10 WT and CHCHD10 P34S are similar whereas the spectra of CHCHD10 R15L and CHCHD10 G66V show an increased a-helical content, especially at 0.1% DPC.
Material, Fig. S2 ), corroborating the specificity of the morpholinobased CHCHD10 knockdown effects. We thus confirmed that knockdown of CHCHD10 expression to approximately half of the normal protein levels results in a robust neuromuscular phenotype in vivo.
Discussion
Here, we show that two motoneuron disease-associated CHCHD10 missense mutations lead to a loss of expression of the mutated allele. Haploinsufficiency is thus the most likely basis for neurodegeneration caused by mutant CHCHD10, as also corroborated by CHCHD10 knockdown data from a vertebrate in vivo model. The clinical phenotypes connected to CHCHD10 R15L and CHCHD10
G66V
, albeit not identical, display similarity including a remarkably slow disease progression even in patients with an otherwise typical disease phenotype (3, 4) . This overlap in clinical syndromes may be explained by the very similar downstream consequences of the mutations, i.e. loss of expression of the two different mutant alleles at mRNA and/or protein level, respectively.
Our data indeed show that CHCHD10 R15L and CHCHD10
are acting at different gene expression levels but with the same consequence, which is loss of expression of the mutated protein. Missense mutations not resulting in a pre-mature termination codon are usually not degraded by nonsense mediated mRNA decay (14) . However, as shown in this study, a single nucleotide substitution of CHCHD10 R15L mRNA is sufficient for a great reduction of the mutated mRNA, possibly by silencing of the mutated allele, changes in mRNA secondary structure or the generation/destruction of binding sites for RNA binding proteins or microRNAs. In the case of CHCHD10
, the mutated mRNA is not aberrantly degraded. However, here the amino acid substitution causes structural changes at the protein level that ultimately result in a faster degradation of the mutant protein.
While a significant reduction of both CHCHD10 R15L and CHCHD10 G66V protein was observed, the p.P34S variant did not alter the folding or stability of CHCHD10 compared with wildtype protein. This finding is in line with several recent reports that, contrary to the initial description of this variant, failed to detect a significant enrichment of p.P34S in ALS patients when compared with healthy controls, arguing against a pathogenic role (12,13). A most recent study (9) suggests that two CHCHD10 mutations, including p.S59L as well as the p.R15L mutation studied in this work, result in impairment of mitochondrial integrity besides reduction in synapse numbers as well as in accumulation of cytoplasmic TDP-43. The authors propose that CHCHD10 mutations act by loss of function or a dominant negative principle. However, Woo et al. do not present CHCHD10 expression data from patient material and heavily rely on overexpression models. In contrast, our results demonstrating loss of expression of CHCHD10 mutant alleles are based on a total of 13 patient cell lines and three different CHCHD10 variants in addition to cell lines from healthy control individuals. In our patient-derived cell lines we could neither observe an alteration of mitochondrial ultrastructure, nor the TDP-43 mislocalization previously reported by Woo et al. upon CHCHD10 knockdown. Of note, during the revision of this manuscript, a parallel publication (15) also reported a normal mitochondrial morphology in patient fibroblasts carrying the CHCHD10 p.R15L mutation. Nevertheless, the detrimental effects of shRNA-mediated CHCHD10 knockdown in vitro and knockout of the CHCHD10 orthologue in C. elegans reported by Woo et al. are in agreement with our claim that haploinsufficiency of CHCHD10 causes motoneuron degeneration. Additionally, our results from CHCHD10 knockdown in the vertebrate in vivo model confirm haploinsufficiency as the molecular basis of CHCHD10-linked neurodegeneration. It remains to be determined, if CHCHD10 mutations other than p.R15L and p.G66V also result in a loss of expression of the mutated protein, or if additional mechanisms are involved. The fact, that overexpression of CHCHD10 R15L leads to a phenotype as reported before (9) underlines the importance of expression studies in patient-derived biomaterial: Cellular pathology upon overexpression of a mutant protein does not necessarily reflect a disease-relevant consequence of the mutation, in particular when studies in human biomaterial reveal that the respective mutant protein is most likely not expressed in patients. The results presented here are critically relevant for the design of future studies to elucidate CHCHD10-related mechanisms of neurotoxicity and motoneuron degeneration in general. While the largest proportion of experimental work on CHCHD10 mutations is based on overexpression systems to date (3, 7, 9) , our data suggest the validity of knockdown paradigms, at least for the two pathogenic mutations analysed in this study. Our findings furthermore underline the critical importance to assess expression also of missense mutations in patient-derived biomaterial before further experimental workup. Finally, we established an in vivo vertebrate model for CHCHD10-associated disorders that may help assessing novel treatment strategies.
Materials and Methods

Ethics statement
Informed written consent was obtained from all individuals donating cells for this study that was approved by the ethical review board according to the Declaration of Helsinki (WMA, 1964). Penicillin/Streptavidin; Fibroblasts: RPMI with 10% FCS, Glutamax, 2.5 mM sodium pyruvate, Uridine, Amphotericine B and Gentamicine; HEK293: DMEM with 10% FCS) HEK293 cells were transfected using calcium phosphate co-precipitation as previously described (17) 
Cell culture
Plasmids
The coding sequences of human wild-type and mutated CHCHD10 (NM_001301339.1) as well as zebrafish (Danio rerio) CHCHD10 (NM_200784.1) including a C-terminal myc-tag were cloned into BamHI and XhoI sites of the mammalian expression vector pCS2þ (RZPD; Tutzing, Germany).
For recombinant protein expression in E. coli, the human CHCHD10 coding sequence was cloned into pGEX-4-T1 (GE Healthcare; Boston, Massachusetts) using BamHI and XhoI sites to express N-terminally GST-tagged human CHCHD10 wild-type and mutants. 
Antibodies used for Western blotting
Immunocytochemistry
Fibroblasts were grown on poly-D-lysine coated cover slips for 48 h. After washing with phosphate buffered saline (PBS) cells were fixed with 4% paraformaldehyde in PBS and permeabilized 
Protein purification and CD spectroscopy
Cultures of E. coli BL21(DE3)pLysS (Merck KGaA; Darmstadt, Germany) transformed with pGEX-4-T1 CHCHD10 wild-type or mutants were induced with 0.1 mM IPTG at an OD 600 of 0.6-0.8. Protein expression was carried out at room temperature for 4 h. Recombinant proteins were purified using Glutathione Sepharose 4B (GE Healthcare; Boston, Massachusetts) according to the manufacturer's instructions. Subsequently, the GST-tag was cleaved using thrombin (GE Healthcare; Boston, Massachusetts) overnight at 4 C. After cleavage, thrombin was removed using p-Amino-benzamidine-agarose (Sigma-Aldrich Co. LLC; St. Louis, Missouri). Circular dichroism (CD) spectroscopy was performed in PBS with addition of 0.02% or 0.1% dodecylphosphocholine (DPC) in a Chirascan TM CD Spectrometer (Applied Photophysics Ltd; Leatherhead, United Kingdom).
Zebrafish care and procedures
Adult zebrafish (Danio rerio) were bred and maintained as previously described (19) . Morpholino-modified antisense oligonucleotides (MO, morpholino) directed either against the translation initiation site (MO1; 5'-GACTGCGACTTCCTCTTGCCATTTC-3'; 100 lM) or a splice junction site (MO2 splice junction: exon1-intron1; 5'-CTACTGCATCTAAAGATACCTCGCT-3'; 300 lM) of zebrafish CHCHD10 were injected into fertilized wild-type zebrafish oocytes in the one cell stage using a FemtoJet microinjector (Eppendorf AG; Hamburg, Germany). A Morpholino Standard Control oligo (CoMO; 5'-CCTCTTACCTCAGTT ACAATTTATA-3'; 300lM) was used as control. All MOs were obtained from Gene Tools, LLC (Philomath, Oregon) and were solved in 200 mM potassium chloride.
For rescue experiments, capped sense mRNA was in vitro transcribed from pCS2þ plasmid coding for C-terminally myctagged zebrafish CHCHD10 using the mMESSAGE mMACHINE SP6 Transcription Kit (Thermo Scientific TM ; Waltham, Massachusetts) and coinjected (200 ng/ml in 200 mM potassium chloride) with MO2. 'Flight response and birefringence were measured at 48 h post fertilization (hpf) and 72 hpf, respectively, as previously described (20) . To inhibit pigmentation, embryos were treated with 0.003% 1-phenyl-2-thiourea prior to microscopic analysis. For motoneuron stainings embryos were fixed at 48 hpf with Dent's fixative (4: 1 MeOH/DMSO) overnight at room temperature, rehydrated with MeOH/PBT (PBS þ 0.1% Tween-20) in three steps with 20 min each and unspecific binding sites were blocked using 10% FCS in PBT (90 min at room temperature 
Transmission electron microscopy
For transmission electron microscopy (TEM), patient-derived cells were kept on carbon-coated sapphire discs for at least 48 h. LCLs were prefixed using 0.1% glutaraldehyde, 4% paraformaldehyde and 1% saccharose in 0.1 M phosphate buffer (pH7.3). After high-pressure freezing cells were freeze-substituted with 0.2% osmium tetroxide, 0.1% uranyl acetate and 5% of water in acetone (22) and embedded in epon. Fibroblasts were high-pressure frozen without prefixation and freeze-substituted as described above. Zebrafish embryos at 48 hpf were fixed with 2.5% glutaraldehyde, post-fixed in 2% osmium tetroxide and dehydrated using a stepwise increase of isopropanol concentration, contrasted with uranyl acetate and embedded in epon. Images of ultrathin sections (80 nm) were taken using a JEOL JEM-1400.
Mass spectrometry
Sample preparation Zebrafish embryos were lysed by addition of lysis buffer containing 6 M guanidine hydrochloride, 10 mM TCEP [Tris(2-carboxyethyl)phosphine hydrochloride], 40 mM 2-chloroacetamide and 100 mM triethylammonium bicarbonate (TEAB) followed by sonication and heating at 90 C for 5 min. The lysates were centrifuged at 10 000 Â g for 30 min at 4 C and the supernatant was collected for further analysis. Protein concentration was determined using the Pierce TM BCA Protein Assay Kit (Thermo Scientific TM ; Waltham, Massachusetts).
Protein digestion was performed with a filter-aided sample preparation (FASP) protocol. In brief, the lysates were buffer exchanged with 50 mM TEAB (4Â) using a Microcon-30 kDa centrifugal filter (Merck Chemicals GmbH; Darmstadt, Germany) and concentrated on the filter. 50 ml of trypsin/LysC (Promega; Madison, Wisconsin) in 50 mM TEAB were added to a final protein-toenzyme ratio of 50: 1. Digestion was performed for 16 h at 37 C and 600 rpm. The resulting peptides were centrifuged through the filter and centrifugation was repeated after addition of 50 ml 0.2% TFA to increase recovery. Both flow throughs were pooled and peptide concentration was determined by absorption at 280 nm.
Label-free quantification of CHCHD10 by parallel reaction monitoring From each sample, 2 mg of digested peptides were adjusted to a volume of 10 ml with 0.5% TFA and 5 ml (1 mg) were injected. The peptides were separated on a 20Â0.075 mm, 3 mm trap column (Thermo Scientific   TM ; Waltham, Massachusetts; PepMap100 C18) and a PepMap100 C18, 500Â0.050 mm, 2 mm analytical column (Thermo Scientific TM ; Waltham, Massachusetts) with a column temperature of 60 C using a Dionex Ultimate3000 RSLCnano system (Thermo Scientific   TM ; Waltham, Massachusetts). Mobile phase of the loading pump (trap column) was 0.05% TFA/2% MeOH (flow rate: 5 ml/min). The mobile phase of the nano pump (analytical column) was A: 4% DMSO/0.1% formic acid and B: 4% DMSO/76% acetonitrile/0.1% formic acid and peptides were eluted with a linear gradient from 1% B to 53% in 21 min (flow rate: 150 nl/min) and infused into a Thermo QExactive mass spectrometer (MS). The MS was run in targeted MS 2 -mode (positive) with a resolution of 35 000, NCE 25, isolation window 1.6 m/z, AGC target 3e6 and max injection time of 128 ms.
For CHCHD10 determination (UniProtID Q6PBP6), parallel reaction monitoring (PRM) was performed for the peptide LPPSQSGPCLFEVR (aa95-108, precursor mass: m/z 793.9) and the y12 (m/z 1376.6627) and y13 2þ (m/z 737.3614) fragments (deviation < 5ppm) were used for label-free quantification with Skyline 3.6 (23) .
Proteomic analysis of zebrafish embryos
The digested peptides from each sample were diluted 1: 1 with 2% TFA and fractionated by strong cation exchange (SigmaAldrich Co. LLC; St. Louis, Missouri; #66889-U) using STAGE Tips. Peptides were eluted using 160 mM ammonium acetate/20% acetonitrile/0.5% formic acid (fraction 1), 300mM ammonium acetate/20% acetonitrile/0.5% formic acid (fraction 2) and 5% ammonium hydroxide/80% acetonitrile (fraction 3). The three fractions were vacuum dried and redissolved in 12 ml 0.5% TFA. Peptide concentration was determined by absorption at 280 nm. From each fraction, 2 mg of peptides were injected using the same instrument configuration and mobile phases as described for the PRM. The peptides were separated with a two-step and three-step linear gradient: fraction 1: 1% B to 20% B from 5 to 120 min, 20% B to 53% B from 120 to 145 min, fraction 2: 1% B to 32% B from 5 to 120 min, 32% B to 53% B from 120 to 145 min, fraction 3: 1% B to 10% B from 5 to 20 min, 10% B to 32% B from 20 to 120 min, 32% B to 53% B from 120 to 145 min. Data were acquired by data-dependent acquisition (Top15) with the following settings: full MS: resolution 70 000, AGC target 3e6, max injection time 120 ms, scan range 400-1400 m/z, MS 2 : resolution 17 500, AGC target 1e6, max injection time 65 ms, isolation window 1.6 m/z, NCE 25 and a dynamic exclusion of 40 s.
Proteins were identified using MaxQuant 1.5.2.8 (24) and the Danio rerio reference proteome from UniProt (downloaded 04 February 2017). Trypsin without cleavage before proline was set as the enzyme allowing up to two missed cleavages, N-terminal acetylation and methionine oxidation were set as variable modifications and carbamidomethylation on cysteine residues as fixed modification. A FDR of 1% was used for peptide and protein identification and protein quantification was performed with the MaxLFQ algorithm (25) . Quantitative analysis of the data was performed with Perseus 1.5.2.6 (26) . Contaminant proteins and proteins identified with < 2 unique peptides were excluded.
Statistical analysis
In total, 7132 proteins were detected and 6116 proteins quantified in all samples were considered. Proteins showing minimal variations (fold change < 6 1.5) between the different conditions were excluded from the analysis. Proteins with a fold change-! 6 1.5 were retained. A two-tailed student's t-test was used to identify differentially expressed proteins between the groups and p-values were corrected for multiple testing using FDRcorrection. FDR-values 0.05 were considered statistically significant. Hierarchical cluster analysis was performed using the Genesis software package (27) .
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